UNSPSC 51286904: Levcycloserine

This classification denotes an enzyme inhibitor with the molecular formula C3H6N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier AK7DRB7FMO, chemically known as 3-isoxazolidinone, 4-amino-, (s)- but more generally known as levcycloserine, which bears US NIH Compound Identifier 401. European Medicines Agency schedules Levcycloserine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08456MIG.

The term LEVCYCLOSERINE is an International Non-Proprietary Name or INN (see World Health Organization INN reference publication, Volume 6, No, 3 1992, List 32). LEVCYCLOSERINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. SMILES: O1NC(=O)C(N)C1.

UNSPSC 51286904 Levcycloserine, a Commodity code, does not align with the state and local procurement activity recently tagged under it. The solicitations filed under this code concern naloxone and drug deactivation systems, therapeutic pharmacy initiatives, medical and first aid supplies for emergency response, and generic pharmaceuticals and over-the-counter products—none of which involve levcycloserine, an antituberculous antibiotic. The mismatch suggests either miscoding in the source data or that this Commodity code currently sees no relevant purchasing activity in the state and local market.

Recent opportunities posted under this code span health agencies and cities across Florida, Texas, and Minnesota. Seminole County, Florida issued an IFB for naloxone and drug deactivation systems (1,900 units annually, due July 26, 2023); the Texas Health and Human Services Commission posted an RFI on April 3, 2026 to gather vendor intelligence on direct-to-manufacturer prescription programs; the City of Tampa issued an ITB on March 25, 2026 for medical and first aid supplies ($700,000 estimated contract value, designated as a sheltered market for certified Small Local Business Enterprises); and the Minnesota Multistate Cooperative Purchasing Alliance posted an RFP on January 20, 2026 for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026. The geographic spread and issuing-body diversity—county health departments, state HHS agencies, municipal fire departments, and cooperative purchasing vehicles—indicate broad procurement interest in pharmaceutical and medical supply categories, though the absence of levcycloserine-specific solicitations suggests this particular Commodity code warrants manual review for correct taxonomy assignment.